Karras Company Inc. Buys Shares of 4,736 Thermo Fisher Scientific Inc. $TMO

Karras Company Inc. bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,736 shares of the medical research company’s stock, valued at approximately $2,744,000. Thermo Fisher Scientific accounts for about 2.6% of Karras Company Inc.’s portfolio, making the stock its 11th biggest holding.

Other hedge funds and other institutional investors have also bought and sold shares of the company. High Note Wealth LLC raised its holdings in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares during the period. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter valued at $31,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.2%

Shares of NYSE:TMO opened at $448.55 on Friday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The firm has a fifty day moving average of $480.25 and a 200 day moving average of $538.17. The firm has a market capitalization of $166.69 billion, a PE ratio of 24.66, a price-to-earnings-growth ratio of 1.99 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The company had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period in the previous year, the business earned $5.15 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on TMO shares. Wells Fargo & Company reduced their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Barclays reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating for the company in a research report on Tuesday, April 14th. Morgan Stanley restated an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $616.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.